First analysis of the Myasthenia Gravis SPOTLIGHT Registry: outcomes with eculizumab and ravulizumab
In routine clinical practice, eculizumab was well tolerated and effective for patients with gMG. Treatment benefits were maintained after transition to ravulizumab.
Authors
- Ema Rodrigues
- Pushpa Narayanaswami (ORCID: https://orcid.org/0000-0002-9412-7349)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Samir Macwan
- Lida Zeinali
- Dubravka Dodig (ORCID: https://orcid.org/0000-0001-5985-3022)
- Michael Pulley (ORCID: https://orcid.org/0000-0003-1879-725X)
- Ashley Yegin
Institutions
- Beth Israel Deaconess Medical Center (US)
- Eisenhower Medical Center (US)
- Harvard University (US)
- University of Toronto (CA)
- University of Florida (US)
- Alexion Pharmaceuticals (United States) (US)
- AstraZeneca (Canada) (CA)
- AstraZeneca (United States) (US)
- Florida College (US)
Publication Details
- Journal
- Journal of the Neurological Sciences
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1016/j.jns.2025.123628
- Citations
- 2
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Amgen
- AstraZeneca
- Sanofi
- Patient-Centered Outcomes Research Institute
- Alexion Pharmaceuticals
- CVS Health
- Argenx
- National Institutes of Health
- EMD Serono